Find and Pitch Jounalists, Get Your Story Covered

Tags: Multiple Myeloma Regimen Comparisons Pharmacist Treatment Selection advice

	Profile	Recent Articles on Subject
1	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Better Quality of Life With RT vs Endocrine Therapy in Older Breast Cancer Patients - 3 months ago Palbociclib Regimen Yields 'Incredible' PFS Gain in Metastatic Breast Cancer - 3 months ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - over 1 year ago
2	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma - 3 months ago
3	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Fixed-Duration Acalabrutinib and Venetoclax Regimens Redefine First-Line Treatment Options for Patients With CLL - 3 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard-of-Care Regimen for Previously Unmanaged CLL - about 1 year ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL - about 1 year ago Assessing Clinical Trial Efficacy vs Real-World Effectiveness in the Treatment of Multiple Myeloma - about 1 year ago Oncology Pharmacists “Approve Every Regimen That Gets Built Into the Oncology EMR,” yet Pharma Often Overlooks Their Role - over 1 year ago
4	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Data Further Confirm Proposed Denosumab Biosimilar Shows Similar Efficacy to Originator - 3 months ago Financial Incentives Increase Utilization of Biosimilars for Oncology Care - 3 months ago Clinical Safety Data Show Switching Between Rituximab Biosimilars Does Not Increase Adverse Events - 3 months ago Non-Medical Switch to Infliximab Biosimilar Demonstrates Similar Outcomes for IBD - 6 months ago Intermittent Fasting and Meal Replacements Improved Short-Term Glycemia - 7 months ago Better Prevention Strategies Rely on the Monitoring of Outpatient Adverse Drug Events - 8 months ago INHALE-3 Study Data Shows Diabetes Care Is Not “One-Size-Fits-All” - 8 months ago Study: Biosimilar Competition Did Not Consistently Lower Costs for Patients - 11 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 11 months ago Experts Establish First Performance Measures of Lifestyle Medicine Treatments - 11 months ago Study: SB17 Shows Biosimilarity to Ustekinumab for Plaque Psoriasis - 12 months ago STRONG-HF: High-Intensity Care Leads to Higher Doses of Guideline Heart Failure Therapy - about 1 year ago Study: Telemonitoring After Heart Failure Comparable to Standard of Care - about 1 year ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - over 1 year ago Study: No Difference Found in Safety of Reference Biologic, Biosimilar - over 1 year ago
5	The Conversation Science Alert Science news. Official account. Australia science news	Ozempic vs Supplements: Dietitian Reveals Truth About GLP-1 Imitations - 3 months ago
6	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more - 3 months ago STAT+: Pharmalittle: We’re reading about Europe’s pharma reform, weight-loss meds, and more - 12 months ago STAT+: Many costly generic drugs are unavailable at Amazon, Cuban, and other alternative pharmacies - about 1 year ago STAT+: Health plan formularies lowered barriers to fair access to some drugs, analysis finds - over 1 year ago
7	Tara Haelle MedPage Today Sci/health journalist. Feminist. Educator. Photographer. Author. DFW science journalismhealthphotographyteaching	ObesityWeek Roundup: Patients More Likely to Ration Obesity Drugs - 4 months ago
8	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	Daily Oral Edaravone for ALS No Better Than On/Off Regimen - 4 months ago
9	Amir Ali, PharmD, BCOP Pharmacy Times Clinical Hem/Onc Pharmacist. USC Assistant Professor. Founder of OncologySolutionsRx. Los Angeles, CA Healthcareoncologypharmacyeducation	Treatment Regimen Considerations - 5 months ago Treatment Opportunities Continue to Advance in CLL Management - over 1 year ago
10	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	2-Drug Regimen Shows Comparable Effectiveness With 3-Drug Regimen to Treat HIV-1 - 7 months ago Durvalumab Shows Improvements in Overall Survival, Progression-Free Survival for Small Cell Lung Cancer - 11 months ago Dramatic Tumor Regression Was Displayed in New Approach to CAR T Therapy - 11 months ago Researchers Compare Reimbursement and Access to New Treatments in European Lung Cancer Care - 12 months ago

Journalists covering Regimen Comparisons